A coterie of drug makers is upset with the Centers for Medicare & Medicaid Services over a proposal they fear would undermine the nascent biosimilar market in the United States. And over the past several weeks, the companies have enlisted the help of more than 70 lawmakers – Republicans and Democrats from both the House and Senate – to convince the federal agency to change its bureaucratic mind.
Read Full Article »
